secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001628280-25-055682
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas reports preclinical data showing ARV-393 + glofitamab combo yields up to 91% TGI in lymphoma model
--------------------------------------------------------------------------------

- ARV-393 (3 mg/kg) + glofitamab achieved 81% TGI (concomitant) and 91% TGI (sequential) vs 38% and 36% single-agent.
- At 6 mg/kg ARV-393 combo, tumor regressions in 10/10 mice (concomitant) and 7/8 (sequential) vs 5/11 and 0/11 alone.
- RNA-seq showed ARV-393 upregulated CD20, interferon signaling, antigen presentation; downregulated proliferation genes.
- Phase 1 trial of ARV-393 in relapsed/refractory non-Hodgkin lymphoma ongoing; clinical data due at medical congress in 2026.
- Company plans to add glofitamab combination cohort in DLBCL to ongoing Phase 1 trial in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/0001628280-25-055682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025055682/arvn-20251206.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-055682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer